AR062666A1 - Benzotriazoles como moduladores de quinasas - Google Patents
Benzotriazoles como moduladores de quinasasInfo
- Publication number
- AR062666A1 AR062666A1 ARP070103923A ARP070103923A AR062666A1 AR 062666 A1 AR062666 A1 AR 062666A1 AR P070103923 A ARP070103923 A AR P070103923A AR P070103923 A ARP070103923 A AR P070103923A AR 062666 A1 AR062666 A1 AR 062666A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- alkyl
- hydrogen
- nr8r9
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, composicion farmacéutica en base al compuesto y uso de estos para preparar medicamentos. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que R es alquilo inferior, hidroxi-alquilo inferior, o un resto elegido entre grupo de formulas (2), en los que cada Ra es con independencia H, alquilo inferior, OH o hidroxi-alquilo inferior; cada Rb es con independencia H, alquilo inferior, halogeno, nitro o halo-alquilo inferior; p es el numero 1, 2, 3 o 4; X es O, CR4R5, C(=O) o S(O)x; R1 es hidrogeno, halogeno, alquilo o NH2; cada uno de R3 es con independencia halogeno, -NO2, alquilo inferior, -CN, -OR7, -NR8R9, -C(O)-R7, -OC(O)-R7, -CF3, -CHF2, -SO2-R10, o dos de R3 forman alquileno-dioxi; R4 es hidrogeno, alquilo inferior, ciano, -(CH2)nOR7, -(CH2)nNR8R9, -(CH2)n-C(O)-NR8R9, -(CH2)n-OC(O)-NR8R9, -(CH2)n-C(O)-OR7; -NR7-SO2-R10, -(CH2)n-NR8-C(O)-R11 o -(CH2)n-NR8-C(O)-OR6; R5 es hidrogeno o alquilo; o R4 y R5 juntos forman alquileno-dioxi; R6 es hidrogeno, alquilo inferior, heteroalquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R10 es alquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R1 es alquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R11 es alquilo, cicloalquilo, heteroalquilo o (heterociclil)alquilo; R2 y R7 son con independencia entre si hidrogeno o alquilo inferior; R8 es hidrogeno, alquilo inferior, o acilo; R9 es hidrogeno, alquilo inferior, heteroalquilo, arilo, heteroarilo, heterociclilo, cicloalquilo; o R8 y R9 junto con el átomo de nitrogeno al que están unidos forman un heterociclilo que contiene por lo menos un átomo de nitrogeno en el anillo, opcionalmente sustituido por OH, oxo, alquilo inferior, alcoxi inferior o acilo; cada uno de m y x es con independencia un numero entero de 0 a 2; Y es hidrogeno, -(CH2)n-OR7, -(CH2)n-C(O)-R7 o-(CH2)n-C(O)-OR7; cada uno de y y z es con independencia el numero 0 o 1; y n es un numero entero de 0 a 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84309006P | 2006-09-08 | 2006-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062666A1 true AR062666A1 (es) | 2008-11-26 |
Family
ID=38893293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103923A AR062666A1 (es) | 2006-09-08 | 2007-09-06 | Benzotriazoles como moduladores de quinasas |
Country Status (17)
Country | Link |
---|---|
US (1) | US8962622B2 (es) |
EP (1) | EP2066319B1 (es) |
JP (1) | JP5325783B2 (es) |
KR (1) | KR101177729B1 (es) |
CN (1) | CN101511359B (es) |
AR (1) | AR062666A1 (es) |
AT (1) | ATE543498T1 (es) |
AU (1) | AU2007293917B2 (es) |
BR (1) | BRPI0717035B8 (es) |
CA (1) | CA2662998C (es) |
CL (1) | CL2007002572A1 (es) |
ES (1) | ES2378577T3 (es) |
IL (1) | IL197015A (es) |
MX (1) | MX2009002229A (es) |
PE (1) | PE20080659A1 (es) |
TW (1) | TW200819440A (es) |
WO (1) | WO2008028860A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
RU2493155C2 (ru) | 2006-12-08 | 2013-09-20 | Ф.Хоффманн-Ля Рош Аг | Замещенные пиримидины и их применение в качестве модуляторов jnk |
EP2426109B1 (en) * | 2007-10-23 | 2013-12-18 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
CN102015689B (zh) * | 2008-05-16 | 2014-01-08 | 霍夫曼-拉罗奇有限公司 | Jnk的抑制剂 |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2010097335A1 (en) | 2009-02-24 | 2010-09-02 | F. Hoffmann-La Roche Ag | Imidazo [1, 2 -a] pyridines as jnk modulators |
MX2012001449A (es) | 2009-08-10 | 2012-03-26 | Hoffmann La Roche | Inhibidores de cinasas c-jun-n-terminales (jnk). |
WO2011151357A1 (en) * | 2010-06-04 | 2011-12-08 | F. Hoffmann-La Roche Ag | Inhibitors of jnk |
RU2572247C2 (ru) * | 2010-06-04 | 2016-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные 2-амино-пиримидина в качестве ингибиторов jnk |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
KR101860971B1 (ko) * | 2011-02-09 | 2018-07-05 | 더루우브리졸코오포레이션 | 아스팔텐 분산제 함유 윤활 조성물 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2014128669A2 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
PL3013353T3 (pl) | 2013-06-26 | 2021-09-20 | Xigen Inflammation Ltd. | Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
JP2017518333A (ja) * | 2014-06-16 | 2017-07-06 | アリンキー バイオファーマAllinky Biopharma | 神経系の変性疾患を治療及び予防するためのp38及びjnk mapk阻害剤 |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
CN108117523B (zh) * | 2016-11-29 | 2021-05-07 | 上海医药工业研究院 | 卤代尿嘧啶类化合物的制备方法 |
US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
BR112020016929A8 (pt) | 2018-02-20 | 2022-06-28 | Agios Pharmaceuticals Inc | Métodos de uso para derivados de benzotriazol trissubstituídos |
WO2022059700A1 (ja) * | 2020-09-15 | 2022-03-24 | 田辺三菱製薬株式会社 | トリアジン化合物の塩、その結晶形及び製造方法 |
CN114456126A (zh) * | 2022-02-26 | 2022-05-10 | 郑州萃智医药科技有限公司 | 一种化合物的合成方法 |
CN115677595B (zh) * | 2022-10-26 | 2024-06-14 | 江苏睿实生物科技有限公司 | 一种2,4,5-三氯嘧啶的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
JP4688876B2 (ja) | 2004-06-10 | 2011-05-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
KR20090007347A (ko) | 2006-03-22 | 2009-01-16 | 버텍스 파마슈티칼스 인코포레이티드 | 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제 |
-
2007
- 2007-08-30 ES ES07803049T patent/ES2378577T3/es active Active
- 2007-08-30 CA CA2662998A patent/CA2662998C/en active Active
- 2007-08-30 MX MX2009002229A patent/MX2009002229A/es active IP Right Grant
- 2007-08-30 WO PCT/EP2007/059040 patent/WO2008028860A1/en active Application Filing
- 2007-08-30 CN CN2007800334496A patent/CN101511359B/zh active Active
- 2007-08-30 AU AU2007293917A patent/AU2007293917B2/en active Active
- 2007-08-30 AT AT07803049T patent/ATE543498T1/de active
- 2007-08-30 BR BRPI0717035A patent/BRPI0717035B8/pt active IP Right Grant
- 2007-08-30 EP EP07803049A patent/EP2066319B1/en active Active
- 2007-08-30 KR KR1020097004741A patent/KR101177729B1/ko active IP Right Grant
- 2007-08-30 JP JP2009527118A patent/JP5325783B2/ja active Active
- 2007-09-05 CL CL200702572A patent/CL2007002572A1/es unknown
- 2007-09-05 TW TW096133095A patent/TW200819440A/zh unknown
- 2007-09-06 PE PE2007001197A patent/PE20080659A1/es active IP Right Grant
- 2007-09-06 AR ARP070103923A patent/AR062666A1/es active IP Right Grant
- 2007-09-07 US US11/899,758 patent/US8962622B2/en active Active
-
2009
- 2009-02-12 IL IL197015A patent/IL197015A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN101511359A (zh) | 2009-08-19 |
CN101511359B (zh) | 2012-09-05 |
WO2008028860A1 (en) | 2008-03-13 |
JP5325783B2 (ja) | 2013-10-23 |
KR20090040908A (ko) | 2009-04-27 |
JP2010502668A (ja) | 2010-01-28 |
IL197015A0 (en) | 2009-11-18 |
US8962622B2 (en) | 2015-02-24 |
US20080103142A1 (en) | 2008-05-01 |
ES2378577T3 (es) | 2012-04-16 |
EP2066319B1 (en) | 2012-02-01 |
TW200819440A (en) | 2008-05-01 |
BRPI0717035B1 (pt) | 2021-05-04 |
KR101177729B1 (ko) | 2012-09-07 |
PE20080659A1 (es) | 2008-05-17 |
CA2662998A1 (en) | 2008-03-13 |
CL2007002572A1 (es) | 2008-04-18 |
BRPI0717035B8 (pt) | 2021-05-25 |
IL197015A (en) | 2013-12-31 |
AU2007293917B2 (en) | 2013-01-31 |
CA2662998C (en) | 2015-10-06 |
EP2066319A1 (en) | 2009-06-10 |
ATE543498T1 (de) | 2012-02-15 |
BRPI0717035A2 (pt) | 2014-11-25 |
AU2007293917A1 (en) | 2008-03-13 |
MX2009002229A (es) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
AR035548A1 (es) | Compuestos organicos | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
CO6241110A2 (es) | Analogos deamidas heteroarilicas como antagonistas del p2x7 | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR067759A1 (es) | Compuestos de pirazol utiles como moduladores de la enzima raf asociada al crecimiento celular anormal | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
AR091400A2 (es) | Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos | |
AR079634A1 (es) | Inhibidores del virus de la hepatitis c | |
AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
AR059886A1 (es) | Derivados de amidas como inhibidores de renina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |